Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

MediSieve Continues Growth Trajectory with Latest Award

MediSieve Continues Growth Trajectory with Latest Award
Created on 13-11-2019

Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical o...
National News Coverage for MediSieve

National News Coverage for MediSieve
Created on 13-11-2019

Founder and CEO, Dr George Frodsham, speaks to the Telegraph on the birth and journey of MediSieve....